“…Performance data from clinical trials, sponsored by Neopath, Inc., were included in the submission to the FDA for pre-market approval of AutoPap 300 QC as a rescreening device for quality assurance (38)(39)(40). Another study, performed independently of the manufacturer, has also evaluated the performance of the device.…”